fr
Gustave Roussy 114, rue Édouard-Vaillant 94805 Villejuif Cedex - France Switchboard:
+33 (0)1 42 11 42 11
GUSTAVE ROUSSY 1st cancer center in Europe
© 2006-2015 Gustave Roussy – All rights reserved
Gustave Roussy is part of the best represented institutions at ASCO annual meeting.
The Highly Cited Researchers 2020 list, published by Web of Science Group (Clarivate Analytics), identifies the most influential researchers as determined by their peers all around the world.
Gustave Roussy is in 5th position worldwide and 1st hospital outside of the United States, according to the World’s Best Specialized Hospitals 2021 ranking by Newsweek magazine
The Minister of Health and Solidarity, Madame Agnès Buzyn, appointed Professor Jean-Charles Soria as General Director of Gustave Roussy
The Highly Cited Researchers 2019 List, published by Web of Science Group (Clarivate Analytics), identifies the most influential researchers as determined by their peers all around the world.
Gustave Roussy, leading European Cancer Centre, is collaborating with 16 international partners in the Oncobiome consortium. The objective of the programme is to determine the relationship between intestinal microbial signatures (GOMS) and the incidence, prognosis and resistance to treatment (and toxicity of this) in cancers of breast, colon, lung...
Immunotherapy boosts the immune system to fight cancer cells. Gustave Roussy is a pionner in immunotherapy and the largest tratment facility in Europe. Between 2013 and 2018, 241 immunotherapy-based clinical trials were implemented at the Insitute and 3,317 patients have been treated with immunotherapy.
By their participation in the initial...
As every year for almost 55 years, the world’s leading cancer experts will meet in Chicago to talk about the latest advances in clinical oncology at the international meeting of the American Society of Clinical Oncology (ASCO).
Gustave Roussy's researchers found an unkown ability to PARP inihibitors - a precision cancer drug used against breast and ovarian cancer - to stimulate the immune system. This study suggests to developp new combinaisons of treatments with immunotherapy.